Trial Profile
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 27 May 2012 Additional location (Singapore), actual initiation date (May 2007) added and official title amended as reported by ClinicalTrials.gov.
- 27 May 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 27 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01606371).